# Camrelizumab With Famitinib for Patients With Rare Head and Neck Malignancies

> **NCT07662681** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University** · enrollment: 40 (estimated)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** camrelizumab with famitinib

## Key facts

- **NCT ID:** NCT07662681
- **Lead sponsor:** Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-01
- **Primary completion:** 2028-07-01
- **Final completion:** 2029-07-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-06-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07662681

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07662681, "Camrelizumab With Famitinib for Patients With Rare Head and Neck Malignancies". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07662681. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*